The cell surface zinc metalloproteinase CDlOlneutral endopeptidase 24.1 1 (NEP) is expressed on normal and malignant lymphoid progenitors, granulocytes, and a variety of epithelial cells. To further define the tissue-specific and developmentally related expression of CDlO/NEP, we have characterized two separate regulatory regions that control the transcription of 5' alternatively spliced CDlOINEP transcripts. These type 1 and 2 CDlO/NEP regulatory regions are both characterized by the presence of multiple transcription initiation sites and the absence of classic TATA boxes and consensus initiator elements. The purine-rich type 1 regula-DIONEUTRAL endopeptidase 24.1 1 (NEP) is a member of a family of membrane-bound metallopeptidases that are expressed in a highly restricted fashion in normal and malignant hematopoietic cells, but are expressed widely in a variety of epithelial cells.I4 CD10, which was originally termed the common acute lymphoblastic leukemia antigen, was first identified as a tumor-associated antigen on the majority of acute lymphoblastic leukemias and additional lymphoid malignancies with an immature phenotype.'.2 However, CD10 is also expressed by normal lymphoid progenitors that are either uncommitted to B-or T-cell lineage or committed to only the earliest stages of B-cell differentiation. These data have led to the hypothesis that in lymphoid cells, CD IO expression identifies an early stage in lymphoid ontogeny. However, the expression of CDlO/NEP is not restricted to lymphoid cells; the enzyme is also found on circulating neutrophils and nonhematopoietic cell types including bronchial epithelial cells, bone marrow stromal cells, renal proximal tubular epithelium, fetal intestine, and certain solid tumor cell lines.'.2
tory region, which includes 5' UTR exon 1 sequence, is characterized by multiple putative PU.l binding sites and consensus ets-binding motifs. In marked contrast, the GC-rich type 2 regulatory region contains multiple putative Spl binding sites, a potential consensus retinoblastoma control element (RCE), and an inverted CCAAT box. In the majority of tissues examined to date, type 2 CDlO/NEP transcripts were more abundant; the abundance of type 1 transcripts was more variable, with the highest type 1 levels in fetal thymus and certain lymphoblastic leukemia cell lines.
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CDIO/NEP also regulates the growth and maturation of early lymphoid progenitors."." In both in vitro" and in vivo" murine assays, inhibition of cell surface CDlO/NEP increased the development of B-cell progenitors from uncommitted murine hematopoietic stem cells. Although the CDIO/NEP peptide substrate that stimulates lymphoid progenitors has not yet been identified, the enzyme appears to have an important regulatory role in early B-lymphopoiesis.
Because CDIO/NEP functions as part of a regulatory loop that controls local concentrations of peptide substrates and associated peptide-mediated signal transduction, it is of interest that CDlO/NEP levels vary with cellular activation and proliferation.' For example, phorbol ester treatment of acute lymphoblastic leukemia cells,'' epithelial cells,I3 and granulocyte^'^ reduces CDIO/NEP proteins and transcripts, whereas de~amethasone'~ or additional factors such as f-MLP, granulocyte-macrophage colony-stimulating factor (GM-CSF), tumor necrosis factor, and C5a" upregulate the enzyme. Recent studies have also linked CDIO/NEP expression with cellular proliferation in primary epithelial malignancies, non small cell carcinoma cell lines, and fetal airway epithelial cells.17 In these studies, CDIO/NEP expression was inversely correlated with that of the proliferating cell nuclear antigen (PCNA).I7 Consistent with this observation, CD10/ NEP expression was least abundant when the largest number of bronchial epithelial cells were actively dividing. 17 The important regulatory roles of CDlONEP and its known relationship to cellular activation and proliferation prompted us to further characterize its 5' sequence. In earlier studies, we demonstrated that the CDlO/NEP gene contains two different 5' exons (exons 1 and 2a/b) that splice into a common exon (exon 3) that contains the translation initiation codon.lX Three types of CDIO/NEP transcripts result from alternative splicing of these specific S' untranslated regions (UTRs). In type 1 transcripts, exon 1 splices directly into exon 3 (Fig l) , whereas type 2a transcripts use an internal S' splice site, and type 2b transcripts use the second S' splice site in exon 2 (Fig l) .
The unique S' untranslated regions in the alternatively spliced types 1 and 2 cDNAs prompted speculation regarding multiple potential CD 1 O/NEP promoters with different transcriptional requirements. Because alternative promoters have been linked to tissue-andor developmental stage-specific gene and because CDlO/NEP is both tissuespecific and developmentally regulated,' these issues were of particular interest. In addition, another member of the family of membrane-bound metallopeptidases, CD 13/aminopeptidase N, has alternative promoters that govern its tissuespecific expression.20 Herein we identify and characterize two unique CDlOlNEP S' regulatory regions.
MATERIALS AND METHODS

Characterization nf 5' Ends of Alternatively Spliced
CDIO/NEP Transcripts
Anulvsis ofthe S' CDIWNEP genomic clone. A previously isolated A phage clone of the most S' region of the CDIOiNEP gene (X EC14-I)IX was digested with EcoRT to isolate an approximately 5-kb fragment that contained exons 1 through 4 and additional 5' UTR sequence. After the approximately S-kb EcoRT S' CDIO/NEP genomic fragment was subcloned into Bluescript (Strategene, La J o b , CA), an approximately 1.84-kb fragment that extended S' of exon I and the 3' of exon 2b was fully sequenced (Fig 2) .
Kupid ampl(fication of cDNA ends. The 5' ends of the alternatively spliced exon 1 -, 2a-, and 2b-containing CDIO/NEP transcripts were initially characterized using a modified rapid amplification of cDNA ends (RACE) protocol" (Fig 3) . In brief, 5' alternatively spliced CDIONEP cDNA templates were synthesized using AMV reverse transcriptase (Promega, Madison, W[), S pg of Nalm-6 RNA, and an exon-specific antisense primer derived from exon 1,2a, or 2b (GSP-RT; step 1, Fig 3) . Resulting single-stranded cDNA templates derived from exon I , 2a, or 2b were subsequently polyadenylated with terminal deoxynucleotidyl transferase (Tdt; GlBCO BRL, Gaithersburg, MD) (step 2 , Fig 3 ) . Thereafter, the Tdt-tailed cDNA was amplified by polymerase chain reaction (PCR). The first round of amplification (30 cycles) used the two 5' sense oligonucleotides R,,R,-TTTT and R(, and the 3' antisense oligonucleotide GSPl (step 3 Fig 3) ; the second round of amplification (30 cycles) included the 5' sense oligonucleotide R, and the 3' antisense oligonucleotide GSP2 (step 4, Fig 3) . The resulting exon 1-, 2a-, and 2b-specific amplified cDNA products were then subcloned into the TA cloning vector (Invitrogen, San Diego, CA) and sequenced to further characterize their 5' ends.
RNase Protection Assuy
The transcription initiation sites of the alternatively spliced CDIO/ NEP cDNAs were further characterized using RNase protection assays.*' DNA fragments containing base pairs 241 to 600, 1 to 300, and 389 to 638 from exon 1 and its associated S' UTR and base pairs 1278 to 1557 from exon 2 and its associated 5' UTRs were generated by PCR using appropriate oligonucleotide primers (Fig 2,  legend) . The resulting CDIOlNEP PCR fragments were then subcloned into the TA cloning vector and sequenced to rule out PCRinduced mutations. Thereafter, these plasmids were linearised with EcoRV, and ['*P]-uridine triphosphate (UTP; NEN, Boston, MA)-labeled antisense transcripts were prepared with SP6 RNA polymerase (Promega). The single-stranded ["PI UTP-labeled RNA probes were subsequently hybridized at 45°C for 18 hours with S0 pg of Nalm-6 RNA or tRNA (Boehringer Mannheim, Indianapolis, IN). Samples were then treated with RNase A (Sigma, St. Louis, MO) and RNase TI (Boehringer Mannheimj and analyLed by electrophoresis on a 6% polyacrylamide gel. The sizes of the resulting protected fragments were estimated using molecular weight markers derived by digesting pBR322 DNA with Msp I (New England Biolabs, Beverly, MA). For additional fine mapping of the transcription initiation sites, aliquots of the protected fragments were also analyzed on a sequencing gel with molecular weight markers including a DNA sequence ladder and an RNA standard of known molecular weight (1 15 bp).
Analysis of Tissue-Specific Alternatively Spliced CDlO/ NEP Transcripts by RNase Protection Assay
RNase protection assays" were also used to evaluate the relative abundance of exon I-, 2a-, and 2b-containing CDIO/NEP transcripts in specific tissues and cell lines. DNA fragments from CDIONEP exons 1 (135 bp) and 2 (203 bp) had been previously obtained using RNA-based PCR and the indicated primers (exon I , sense S'-ACCAGGGAACTGCTCC-3', antisense 5"AGCCTGCTCTCG-GTCAA-3'; exon 2, sense 5':TCGGGCCGTGGAGGAGG-3', antisense S'AATCTGGTAGCCCCGAT-3'). Exon l -and 2-specific fragments were subsequently cloned into the TA cloning vector (Invitrogen) and sequenced. The plasmids were linearized with EcoRV and used to prepare [12Pl UTP (NEN)-labeled antisense probes with SP6 RNA polymerase (Promega). ["P]-labeled RNA probes derived from exons I and 2 were hybridized with the indicated RNAs (Fig 6) at 45°C for approximately I8 hours. The samples were subsequently treated with RNase A (Sigma) and RNase TI (Boehringer Mannheim) and size-fractionated on a 6% polyacrylamide gel.
Determination o f CDIO/NEP Promotor Activity by Luciferase Assay
The approximately S-kb 5' CDIO/NEP EcoRI genomic fragment that was originally derived from XEC14.1 and subsequently cloned into Bluescript (Fig 2) was used for the generation of CDIO/NEPluciferase constructs. In brief, the CDIO/NEP genomic fragments indicated in Fig 5 were obtained using the appropriate restriction endonucleases and subsequently subcloned into the promoterless luciferase plasmid P X P~.~~ Transient transfections were performed as previously described." In brief, 3.0 X IO' Nalm-6 or 1.5 X IO' bronchial epithelial cells (56 FHTE) were transfected with 20 pg of PXP2 alone, CMV PXP2, or CDIO/NEP PXP2 and 2 pg of the cytomegalovirus-human growth hormone plasmid (CMV-GH) in Iscove's modified Dulbecco's medium (IMDM) or Dulbecco's modified Eagle's medium (DMEM) at 300 or 250 V, 960 pF. Luciferase activity was measured in relative light units (RLU) 8 hours posttransfection using a luminometer (Analytical Luminescence Laboratory, San Diego, CA), and growth horfolding energies. The second part searches the results of the first to assemble a minimum-energy form. When the optimal structure and suboptimal structures that are within 10% of minimum energy are both examined, the program reveals helix formation with 90% confidence." Optimal and suboptimal structures that are within 10% of the minimum energy are superimposed using dot plots of the folded groupings. Dot plots of the folded structures with the highest groupings have the highest probability of helix formation in the identified regions. We predicted the optimal secondary structure for the CDlO/NEP
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RESULTS
Characterization of the 5' Ends of Alternatively Spliced
CD1 OLVEP Transcripts
We used a modified RACE protocol2' (Fig 3, cDNA clones were isolated using exon l-specific antisense primers, and sequence analysis indicated that each cDNA extended into the region of base pairs 324 to S29 (Fig 2) . When exon 2a-or 2b-specific antisense primers were used, five exon 2a-containing cDNA clones and three exon 2b-containing cDNA clones were isolated; all of these clones extended into the region of base pairs 1388 to 1486 (Fig 2) .
To more definitively identify CDlO/NEP transcription initiation sites, we performed RNase protection assays with individual probes designed to encompass putative initiation sites S' to exons 1 and 2 (Fig 4) . To further characterize exon I -containing transcripts, a ["P] UTP-labeled singlestranded RNA probe was synthesized that corresponded to base pairs 241 to 600 of the CDlO/NEP genomic sequence (Fig 2) . In addition to protecting a major fragment consistent with a S 12-bp initiation site, the probe also protected a minor full-length fragment, suggesting that there was another initiation site S' to base pair 241 (data not shown). For this reason, two additional ["P] UTP-labeled RNA probes of base pairs 1 to 300 and 389 to 638 were synthesized. As indicated in Fig 4, lanes l and 3 , the base pair 389 to 638 exon 1 probe protected a major fragment of 127 nucleotides, whereas the base pair 1 to 300 exon 1 probe protected a minor fragment of 161 nucleotides. The sizes of these protected fragments identified major and minor transcription initiation sites for exon l-containing transcripts at positions S12 and 140, respectively (Fig 2) . It is likely that the minor initiation site at base pair 140 was not identified by RACE analysis because of premature termination of reverse transcription.
To further characterize exon 2-containing transcripts, a ["P] UTP-labeled single-stranded RNA probe was synthesized corresponding to base pairs 1278 to 1557 (Fig 2) . As indicated in Fig 4, this probe protected one major 105-bp and two minor 133-bp and 155-bp fragments, identifying major and additional minor transcription initiation sites at base pair positions 1453, 1425, and 1403, respectively (Fig  2) . Because neither exon 1-nor 2-containing cDNAs were preceded by a TATA box or consensus initiation element" (Fig 2) , these multiple transcription initiation sites were not unexpected.
Churucterization of Types I and 2 CDIOhVEP Promoters
The identification of distinct initiation sites for types 1 and 2 CDlO/NEP transcripts suggested that these transcripts were controlled by separate regulatory elements. For this reason, four specific fragments from the S' CDlO/NEP genomic region (base pairs 1 to 632, 1 to 981, 1067 to 1.599, and 1067 to 1805, respectively; Fig S ) were subcloned into the promoterless luciferase vector, pXP2. Thereafter, the CD1 01 NEPi Nalm-6 acute lymphoblastic leukemia cells and S6 FHTE bronchial epithelial cells were cotransfected with CDlO/NEP pXP2 and CMV-GH constructs. Transfectants were then analyzed for luciferase activity, and luciferase activity was normalized for transfection efficiency by evaluating supernatants from the transfectants for simultaneous growth hormone secretion.
As indicated, the base pair 1067 to 1599 type 2 CD101 NEP construct directed luciferase activity in both the S6 Although the CDIONEP construct containing base pairs 1 to 632, (5 1 1 bp 5' and 121 bp 3' to the type 1 major transcription initiation site) had minimal type I promoter activity in S6 FHTE cells, the addition of 349 3' nucleotides increased the activity of this regulatory element (Fig 5) . Furthermore, the two type I constructs were somewhat more active in Nalm-6 acute lymphoblastic leukemia cells than in 56 FHTE cells. Potential tissue-specific differences in the activities of the type I promoter are of interest because this purine-rich sequence contains clusters of putative PU. I binding sites and consensus motifs for ets-family transcription factors (Fig 2) . The type 1 regulatory region preceding both type I transcription initiation sites also contains a short segment of dinucleotide TG repeats (base pairs 22 to 65) that may induce conformational changes in the DNA helix that result in altered DNA-protein interactions."
123-
Tissue-Spec@ Expression of the Alternatively Spliced
CDIOAJEP Transcripts
Because promoters with different transcriptional requirements are often involved in controlling tissue-specific gene expression" and because CDIONEP is expressed in a variety of both hematopoietic and nonhematopoietic cells,' we evaluated the relative abundance of types 1 and 2 transcripts in a variety of cell types using the previously described transcript-specific RNase protection assay (Fig l) . In this assay, single-stranded anti-sense ["P] UTP-labeled probes specifically protect exon !-containing transcripts (protected fragment, 135 bp) or exon 2a-or 2b-containing transcripts (2a protected fragment, 115 bp, 2b protected fragment, 203 bp) that can be distinguished on the basis of size (Fig 6) .
As predicted by the previous luciferase assays (Fig 5 and  data not shown) , type 2 transcripts were more abundant than type 1 transcripts in a variety of cell types (Fig 6) . However, the abundance of type 1 transcripts varied significantly in different cell types, suggesting that this mRNA might be transcribed in a more restricted manner (Fig 6) .
For example, normal and malignant lymphoid progenitors (fetal thymocytes and pre-B cell acute lymphoblastic leukemia cell lines Nalm-6 and REH) had significantly higher levels of type 1 CDIONEP transcripts; fetal kidney and a glioblastoma cell line (A172) also had higher relative levels of type 1 transcripts (2x1 relative ratios, 1.0 to 2.5; Fig 6) . These data are of interest because the type 1 regulatory element was somewhat more active in Nalm-6 cells than in 56 FHTE cells (Fig 5) and because PU. 1 and other ets-family transcription factors have been linked to the tissue-specific expression of specific gene products in the lymphoid sys-
The relative abundance of type 1 and 2 transcripts in cell lines with weak CDIO/NEP-driven luciferase activity prompts speculation regarding additional elements that may enhance CDIONEP promoter activity. were subcloned into the promoterless luciferase vector, pXP2. The 56 FHTE bronchial epithelial cell lines and Nalm-6 acute lymphoblastic leukemia cell lines were cotransfected with either PXP, alone, CMV PXP2, or one of the CDlOlNEP PXP, constructs and the CMV growth hormone construct. Thereafter, RLU from the individualized transfections were normalized for transfection efficiency by standardizing RLU for growth hormone production driven by the CMV-GH internal standard after subtraction of background PXP, activity. Promoter activity (RLUlnglmL and percent maximum CDlOlNEP-driven activity) represent mean and SEs for t w o separate experiments performed in triplicate for each cell line. Differences between the percent maximum CDlOINEP-driven activity of the base pairs 1 t o 632 type I construct in Nalm-6 and 56 FHTE cells are of borderline significance (P = .08) using a one-sided Student's t test. Luciferase activity of base pairs 1 t o 981 type 1 CDlOlNEP PXP. construct was 2.6 t 0.4 times and 2.7 ? 0.3 times higher than that of PXP, alone in Nalm-6 and 56 FHTE cells, respectively. Luciferase activity of base pairs 1067 t o 1599 type 2 CDlOlNEP PXP2 construct was 3.7 ? 0.4 times and 5.7 ? 0.9 times higher than that of PXP2 alone in Nalm-6 and 56 FHTE cells, respectively. Evaluation of type 1.2a. and 2b transcripts in CDlOlNEP-positive cell types by RNase protection assay. The relative abundance of type 1.2a. and 2b transcripts were evaluated in the noted cell lines and primary tissue samples using a transcript-specific RNase protection assay. This assay used singlestranded antisense probes that specifically protected exon l-containing transcripts (protected fragment 135 bp), exon Za-containing transcripts (protected fragment, 115 bp), or exon 2b-containing transcripts (protected fragment, 203 bp) (Fig 1) .
CDlO/NEUTRAL ENDOPEPTIDASE 24.1 1 PROMOTERS 3205 base pair 242 to 285 putative stem loop occurs between the minor (base pair 140) and the major (base pair 512) type 1 transcription initiation sites, and the second putative stem loop (base pairs 835 to 896) occurs in the middle of exon 1, potentially affecting transcription through this region. Furthermore, the third predicted stem loop (base pairs 1486 to 1597) is located immediately 3' to the type 2 major transcription initiation site. Stable 5' stem loops have been linked to reduced mRNA translation efficiency3' and premature transcription terminati~n,~' prompting speculation that CDlO/ NEP 5' secondary structure may also influence differential expression of type l and 2 transcripts.
DISCUSSION
We have identified two separate regulatory regions that control the transcription of 5' alternatively spliced CD10/ NEP transcripts. These type l and 2 CDlO/NEP regulatory regions are both characterized by the presence of multiple transcription initiation sites and the absence of classic TATA boxes and consensus initiator elements. The purine-rich type 1 regulatory region, which includes 5' UTR exon 1 sequence, is characterized by multiple putative PU. l-binding sites and consensus ets-binding motifs. In marked contrast, the GCrich type 2 regulatory region contains multiple putative Splbinding sites, a potential consensus retinoblastoma control element (RCE); and an inverted CCAAT box. In the majority of tissues examined to date, type 2 CDlO/NEP transcripts were more abundant, with ratios of 2a:2b transcripts of approximately 2 to 3: 1. The abundance of type 1 transcripts was more variable, with the highest type 1 levels in fetal thymus and certain lymphoblastic leukemia cell lines.
The purine-rich type 1 regulatory region is of particular interest because CDlO/NEP is expressed in a restricted population of early lymphoid progenitors and also in neutrophils. PU.l is a member of the ets family of transcription factors and is identical to the Spi-l proto~ncogene.'~ Highly expressed in B cells and macrophages, PU.l regulates B-cell genes including immunoglobulin K light chain,32 p heavy and J chain,34 and macrophage genes including CD1 lb35 and the M-CSF re~eptor.~' Furthermore, recent studies have shown that PU.l is developmentally upregulated during normal human myelopoiesis and is required for the earliest stages of in vitro hematop~iesis.~~ In luciferase assays, additional sequence from the 5' UTR of exon 1 increased type 1 CDlO/NEP promoter activity (Fig  5) . Therefore, it is of note that the 5' UTR of exon 1 contains additional consensus binding motifs for ets family members, including an additional potential PU. 1 binding site. Recently characterized longer 5' type 1 elements also contain additional ets consensus motifs (data not shown). These data are of interest because two ets family members (PU.1 and ets-1) are required for the expression of certain B-cell products, such as the immunoglobulin p heavy chain. 33 The consensus ets-binding motifs in the CDlO/NEP type 1 regulatory region contain the core GGAA sequence that was originally identified in the polyoma enhancer (PEA3).3x Multiple ets family members have been reported to bind to this purine-rich sequence, including the recently characterized PEA3 transcription factor." This PEA3 transcription factor is particularly abundant in brain, which is interesting given the abundant type 1 CDlO/NEP transcripts in the glioblastoma cell line (Fig 6) .
The GC-rich type 2 regulatory region, which has CpG islands39 and no apparent TATA box, is similar to the promoters of many previously reported housekeeping genes4' These housekeeping genes have common features that are shared by the type 2 CDIONEP promoter, including a wide tissue distribution, a low constitutive level of expression, and multiple transcription initiation sites. However, these characteristics are not restricted to promoters of housekeeping genes. For example, the promoters of several oncogenes and growth factor receptor genes, including H -r~s ,~' K -r~s ,~' epidermal growth factor re~eptor:~ insulin receptor," insulin-like growth factor re~eptor,"~ and nerve growth factor receptor% have similar characteristics. Protooncogenes and other growth-related genes commonly have an unusually long (greater than 200 nucleotides) GC-rich 5' UTR47 like that seen in the type 2 CDlO/NEP promoter.
The potential Spl-binding sites in the type 2 CDlO/NEP regulatory region are common in promoters that lack a classic TATA Spl is believed to be critical for the initiation of transcription from TATA-less promoters.49 Although Spl is ubiquitous, its expression varies significantly in different cell types and different stages of de~elopment.~' Given the close association between methylation, GC-rich sequences, and Spl binding, it is also of interest that Spl binds differentially to methylated and unmethylated DNA sequence^.^' Because CDlO/NEP is developmentally regulated in both hematopoietic" and epithelial progenitors,8 it will be important to further characterize the role of methylation and Spl binding in the type 2 promoter.
The type 2 CDlO/NEP regulatory region also contains an inverted CCAAT box, which is a motif that has been implicated in the transcription initiation of cell cycle control genes.52 The GC-rich CDlONEP type 2 promoter, with its potential Spl-binding sites and inverted CCAAT box, resembles that of other proliferation-associated promoters such as thymidine kinase,53 DNA polymerase a,54 and topoisomerase I1 a. 55 These structural similarities are of particular interest because CDlO/NEP expression varies with cellular proliferation in certain cell lines."
The type 2 CDlO/NEP promoter also contains a consensus RCE that is located between a potential Spl-binding site and an inverted CCAAT box. In recent studies, the retinoblastoma protein upregulated Spl -mediated transcription via an incompletely elucidated mechanism that involves the RCE ~equence.~' These data are of particular interest because the retinoblastoma gene is consistently inactivated in SCLC,"' and CDlO/NEP inhibits SCLC growth by hydrolyzing mitogenic peptides produced by these tumor^.^ As previously noted, CDlO/NEP is a member of a family of surface membrane metalloproteinases that are expressed in specific hematopoietic cell types and the luminal surface of epithelial brush borders.' Several of these membrane metalloproteinases participate in the final stages of peptide hydrolysis, and in certain instances, these enzymes function in concert to digest common peptide substrates. Furthermore, certain of these membrane metalloproteinases have common regulatory features, including alternatively spliced 5' UTRs and multiple promoters." By further analyzing the CDIO/ NEP promoter, we may define additional principles that govern the expression of this important family of cell surface enzymes.
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